SDGR Shorts Ease as Analysts Chase a 14% Rally Into Earnings

Schrödinger heads into its November 4 earnings call with short sellers trimming positions, analysts lifting targets in a hurry, and options traders showing almost no interest in downside protection.

The most striking feature of the past two weeks is how quickly the analyst community has repriced its view. Three firms raised their targets between October 12 and October 20, with Keybanc making the boldest move, lifting its target from $20 to $32 while keeping an Overweight rating. TD Cowen followed with a raise to $31, and BMO Capital moved to $30. UBS, which holds a Neutral view, also edged its target higher to $21. That flurry of upgrades points to a broad acknowledgment that the stock's late-September positioning was too pessimistic, though UBS staying at Neutral, with a target still well below the current $26.72 print, signals the Street is not uniformly convinced. The consensus mean target of $25.86 now sits fractionally below where the stock trades, meaning the aggregate Street view, taken at face value, implies the recent rally has already done most of the work the bulls expected.

Short positioning is easing but remains substantial. At 15.7% of free float, short interest is not negligible, though it has drifted lower through October, down roughly 3% on the month and nearly 3% on the week. The borrow market is firmly relaxed: availability is running at 628%, meaning there are more than six shares available to borrow for every one currently lent out, close to the most comfortable conditions seen over the past year, well clear of the 52-week tightest reading of 191%. Cost to borrow at 0.43% is close to risk-free. There is no squeeze pressure here, and the loose availability actually makes it easier, not harder, for new shorts to build positions if sentiment turns. The ORTEX short score of 59 has drifted down from around 63 to 64 earlier in October, consistent with the picture of shorts gradually stepping back rather than capitulating.

Options traders are firmly in the bull camp, and have been for weeks. The put/call ratio at 0.22 is barely above its 20-day average of 0.21, and the z-score of 0.26 suggests no unusual hedging demand at all. For context, the 52-week high on the PCR was 0.69, and the current reading is close to the 52-week low of 0.11. That sustained call skew has coincided with the stock's 14% one-week gain and the 9% single-day jump on October 27. Wikipedia attention for the company is running about 1.3 standard deviations above its own 90-day history, a noticeable pickup in retail interest that aligns with the sharp price move.

BlackRock reported holding 14.1% of shares as of September 30, adding 843,000 shares in the quarter. AQR added roughly 1.5 million shares in the period through June. On the insider side, recent Form 4 activity has been modest and mechanically structured: a director exercised options and sold shares under a pre-arranged 10b5-1 plan in September, and the CFO filed a small plan-driven sale in July. Net insider value over the past 90 days is a negative $941,000, though the 10b5-1 context strips most of the signal from those transactions.

The company has not beaten earnings expectations reliably in recent quarters, with the EPS surprise factor score ranking in the 8th percentile and EPS momentum over both 30 and 90 days sitting at the bottom of the range. The one data point that cuts the other way is historical post-earnings price action: the August 2026 result generated a 13.8% one-day gain and a 19% five-day move. With Q3 results due November 4, that prior reaction is the clearest precedent the data carries, though the current stock price already reflects a sharp pre-earnings move. What to watch next: whether the consensus target can move above the current stock price before the print, and whether short interest continues its gradual retreat or stabilises as traders position around the number.